ResearchMoz

France Diabetes Market Forecast 2011-2016

Publisher Name » IMARC
Published Date » 2011-03-18
No. Of Pages » 38
IMARC’s new report “France Diabetes Market Forecast 2011-2016” provides an analytical and statistical insight into the French diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in France. The report has segmented the French diabetes market into two segments - Insulin and the Oral Antidiabetics market. For each of the aforementioned categories, the report provides historical and future market sales of key classes, key companies, key drugs and key molecules.

The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the French diabetes market till 2016. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the French diabetes market in some form or the other.

Key Questions Answered in this Report:
  • What is the size and demographical breakup of the diabetes population in France?
  • What are the current and future diagnosis and drug treatment rates of diabetes in France?
  • How has the diabetes market behaved since 2005 and what are the expected trends till 2016?
  • What has been the historical performance of the French Insulin market during 2005-2010 and its outlook till 2016?
  • What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during 2005-2010?
  • What has been the historical performance of the Oral Antidiabetics market during 2005-2010 and its outlook till 2016?
  • What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during 2005-2010?
Why should you buy this report?
  • Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in France and identify your potential patient pool.
  • Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics market to identify potential classes, drugs, partners and competitors for market entry and expansion plans.
  • Develop Investment strategies by identifying companies that have been the biggest winners and losers in the French Insulin and Oral Antidiabetics market.
  • Gain an insight into future market events such as biosimilars and new product launches.
Classes Covered:

Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediate acting Insulins, Biguanides, Glitazone and Biguanide combinations, Biguanide and Sulphonylurea combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide combinations, Glitazone and Sulphonylurea combinations, SGLT Inhibitors, SGLT Inhibitor and Biguanide combinations, PTP1B Inhibitors and all other Oral Antidiabetic classes.

Information Sources:

Information has been sourced from both primary and secondary sources:
  • Primary sources include industry surveys and face to face/telephonic interviews with physicians and industry experts.
  • Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases.
Forecasting Methodology:

IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast.
1 Executive Summary
2 Epidemiology
2.1 Total Diabetes Patients
2.2 Patients by Gender
2.3 Patients by Age Group
2.4 Diagnosed and Drug Treated Population
3 Market Dynamics
3.1 Diabetes Market
3.1.1 Current Trends (2005-2010)
3.1.2 Market Forecast (2011-2016)
3.2 Insulin Market
3.2.1 Current Trends (2005-2010)
3.2.1.1 Market by Class
3.2.1.2 Market by Molecule
3.2.1.3 Top Players
3.2.1.4 Top Drugs
3.2.2 Forecast (2011-2016)
3.3 Oral Antidiabetics
3.3.1 Current Trends (2005-2010)
3.3.1.1 Market by Class
3.3.1.2 Top Players
3.3.1.3 Top Drugs
3.3.2 Forecast (2011-2016)
List of Figures
Figure 2 1: France: Number of Diabetes Patients* (in 000’s), 2010, 2015, 2020, 2025 & 2030
Figure 2 2: France: Breakup of Diabetes Patients by Gender (in 000’s), 2010, 2015, 2020, 2025 & 2030
Figure 2 3: France: Breakup of Diabetes Patients by Gender (in %) 2010, 2015, 2020, 2025 & 2030
Figure 2 4: France: Breakup of Diabetes Patients by Age Group (in 000’s), 2010, 2015, 2020, 2025 & 2030
Figure 2 5: France: Breakup of Diabetes Patients by Age Group (in %) 2010, 2015, 2020, 2025 & 2030
Figure 2 6: France: Diagnosed & Drug Treated Share of Population Forecast (in %) 2010, 2015 & 2020
Figure 3 1: France: Diabetes Market (in Million US$), 2005-2010
Figure 3 2: France: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2005-2010
Figure 3 3: France: Diabetes Market Forecast (in Million US$), 2011-2016
Figure 3 4: France Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2016
Figure 3 5: France: Insulin Market (in Million US$), 2005-2010
Figure 3 6: France: Breakup of Insulin Market by Class (in %), 2005-2010
Figure 3 7: France: Insulin Market: Share by Molecules (in %), 2005-2010
Figure 3 8: France: Insulin Market: Share of Key Players (in %), 2005-2010
Figure 3 9: France: Insulin Market: Sales of Key Drugs (in %), 2005-2010
Figure 3 10: France: Insulin Market Forecast (in Million US$), 2011-2016
Figure 3 11: France: Oral Antidiabetics Market, (in Million US$), 2005-2010
Figure 3 12: France: Oral Antidiabetics Market: Share by Class (in %), 2005-2010
Figure 3 13: France: Oral Antidiabetics Market: Share of Key Players (in %), 2005-2010
Figure 3 14: France: Oral Antidiabetics Market: Share of Key Drugs (in %), 2005-2010
Figure 3 15: France: Oral Antidiabetics Market Forecast (in Million US$), 2011-2016
Figure 3 16: France: Oral Antidiabetics Market: Share by Class Forecast (in %), 2010-2016
List of Tables
Table 1 1: France: Oral Antidiabetics & Insulin Definitions
Table 2 1: France: Diagnosed & Drug Treated Population (in Millions), 2010, 2015 & 2020
Table 3 1: France: Breakup of Insulin Market by Class (in Million US$), 2005-2010
Table 3 2: France: Insulin Market: Sales by Molecule (in Million US$), 2005-2010
Table 3 3: France: Insulin Market: Sales of Key Players (in Million US$), 2005-2010
Table 3 4: France: Insulin Market, Sales of Top Drugs (in Million US$), 2005-2010
Table 3 5: France: Oral Antidiabetics Market: Sales by Class (in Million US$), 2005-2010
Table 3 6: France: Oral Antidiabetics Market: Sales of Key Players (in Million US$), 2005-2010
Table 3 7: France: Oral Antidiabetics Market, Sales of Top Drugs (in Million US$), 2005-2010
Table 3 8: France: Oral Antidiabetics Market, New Drug Launches (2011-2016)
Table 3 9: France: Oral Antidiabetics Market by Class Forecast, (in Million US$), 2010, 2013 & 2016

List of Tables


List of Figures

Upcoming Reports:

Customer Experience Management (CEM) & Voice Of Customer (VOC) Analytics - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2018
By - Transparency Market Research
Customer Experience Management (CEM) is getting a lot of attention in the technology market. CEM is a solution through which an organization can interact with their customers and analyze customer behavior, purchasing patterns, satisfaction, complaints, insights and their overall experience. Organizations have to reach out to customers and hence are applying this customer centric approach.  This approach helps organizations to analyze customer insights and also helps the growth of the organization by improving the customer experience and customer loyalty. All organizations...
Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2012 - 2018
By - Transparency Market Research
Molecular diagnostics, also called as MDx, is a branch of in vitro diagnostics that helps in identification of nucleic acids. Molecular diagnostics assist in identifying nucleic acids in foreign organisms or genetic markers of any patient. MDx tests is the fastest growing branch of in vitro diagnostics and its growth is influenced by factors such as rapid turnaround time, high sensitivity, low cost and convenient workflow. It is a highly regulated area of biotechnology and requires 510(k)/IVD clearance. MDx employs different assays and platforms that are paired with several...
Medicated Skin Care Products Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
  Medicated skin care products are those which provide relief from varieties of skin problems such as anti ageing cream for the old age population, creams available for glowing and beautiful skin, protecting hair loss, eczema, rashes and many more. These markets have a great opportunity in niche market due to growing urge for healthy skin. Some of the major factors driving the growth of this market are growing consumer preference towards maintaining healthy and youthful skin and increasing momentum towards taking care of the skin. Due to shifting trends towards preferring...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

                    

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...